The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

Sarcoidosis is a systemic disease of unknown etiology. It is characterized by the presence of non-necrotizing granulomas distributed along the lymphatics in the peribronchovascular (axial ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

It had gotten so bad that his doctor was like, 'You don't have to do it now, but we'll want to consider a lung transplant' ...

The FSR Pilot Grant program, initiated in 2018, seeks to fund innovative research in both clinical and basic science settings ...

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline ...

Neck: No palpable lymph nodes or masses. Chest: Clear to auscultation and percussion. Cardiovascular: S1 and S2 were normal. No gallops or murmurs. Abdomen: Soft and nontender. No palpable ...